-+ 0.00%
-+ 0.00%
-+ 0.00%

JD Health (06618) announces results for the third quarter of 2026: AI+ supply chain two-wheel drive, entering the Expo's “global circle of friends” and further expansion

Zhitongcaijing·11/17/2026 09:49:06
Listen to the news

The Zhitong Finance App learned that on November 17, 2026, JD Health Co., Ltd. (stock abbreviation “JD Health”, stock codes: 06618 [HKD counter] and 86618 [RMB counter]) announced the results for the third quarter of 2026. During the reporting period, JD Health achieved revenue of 20.2 billion yuan and operating profit of 1.57 billion yuan under non-IFRS indicators (non-IFRS). In the third quarter, the company continued to strengthen the core capabilities of the medical and health supply chain, comprehensively deepened the application of AI in all medical service scenarios, and accelerated the consolidation of the offline “medicine, testing, diagnosis, and medicine” closed-loop business format. At the same time, with the help of the 9th CIIE, JD Health's “Global Circle of Friends” was further expanded. While achieving its own steady growth, the trend of high-quality development was remarkable.

More than 50 new drugs were launched in a single season, and the “global circle of friends” of the Expo was expanded

In the third quarter, JD Health continued to lead the industry in the field of new drug launches and cooperation with pharmaceutical companies. As of September 30, 2026, more than 110 pharmaceutical companies have chosen JD Health as their partner to launch new products. In the third quarter, more than 50 new drugs were launched through JD Health, including Yangzijiang Pharmaceutical's innovative drug Paramian®, Jinsei Pharmaceutical's innovative domestic gout drug Jinbeixin®, and Hengrui Pharmaceutical's new drug Hengyi®. At the same time, the company deepened collaboration with partners such as Leo Pharmaceuticals, Genting Xinyao, and Likang Life Technology to jointly explore innovative service models around AI-enabled specialist patient services and management of the entire course of chronic diseases.

While consolidating the supply of pharmaceuticals, JD Health has also made abundant progress in categories and services such as medical devices, nutrition and health care, and pet categories. In terms of high-end medical devices, in the third quarter, the company cooperated with the Boao Lecheng Pioneer Zone Administration to jointly launch the Jingdong Health Boao Lecheng High-end Equipment Center Zone, covering high-end categories such as inspection and diagnosis, health monitoring, rehabilitation and nursing, and promoting new global medical device products to reach domestic users more quickly. In terms of health consumption, the “Medical Gold Selection” product selection mechanism has been comprehensively upgraded, and nearly 20 leading brands such as Johnson & Johnson, Durex, and Kefumei have been joined to promote high-quality medical personal care to the mass market faster. In addition, the company continues to improve the closed loop of “medical examination and drug insurance” health services for pets, cooperates with brands such as Royal to promote the construction of pet prescription food, and optimizes cold chain compliance and service guarantees for pet vaccines.

This ecological advantage of the supply chain was unleashed centrally at the 9th Expo in November. During the fair, JD Health signed centralized contracts with more than 20 global healthcare brands, including Pfizer, Merck, Novo, and Takeda. The cooperation further extended from product launches to patient management, AI innovation, and full-course health management. As of the third quarter, JD Health had launched more than 100 new drugs online, more than the total for the whole of 2025, further consolidating the industry position of “the first platform for the launch of new drugs in the entire network”. At the same time, JD Health continues to enrich global supply through brand cooperation and the launch of new drugs and health products, and the user mentality of “buying the world's best medicines on JD” continues to grow.

In terms of omnichannel fulfillment, the coverage of JD Health's instant drug purchase service and the scale of partner stores have been steadily expanding. Through linking with partner pharmacies, equipped with 24-hour online pharmacist support, and providing 1-on-1 express delivery services, the nighttime drug purchase service has been expanded to more than 300 cities across the country; existing cold chain distribution services have been upgraded in many cities to achieve full temperature control distribution and real-time monitoring of hundreds of drugs, and continuously improve the omnichannel drug fulfillment capabilities.

The amount of interaction between AI doctors “Dawei” increased by more than 5 times, and Medwork Knowledge empowers clinical practice

In the third quarter, JD Health's AI medical service experience continued to be optimized. The number of AI doctor “Dawei” service users continued to grow rapidly, and the average daily AI health service interaction volume increased more than fivefold over the same period last year. In terms of specialist health management, the company collaborated with expert teams such as Professor Wang Xiaoping of the Second Xiangya Hospital of Central South University, Professor Li Zhanjiang of Beijing Anding Hospital, and Professor Yang Dingquan of Sino-Japanese Friendship Hospital to jointly build and launch famous medical intelligence in the fields of skin, psychology, breathing, and chronic metabolism to provide personalized health consultation and long-term continuous follow-up.

Furthermore, Medwork, the AI workbench for doctors under JD Health, has made breakthrough progress. Relying on the “Beijing Medicine Thousand Inquiries” model, MedWork Intellectuals deeply embeds AI into clinicians' workflows, covering diagnosis and treatment support, multidisciplinary consultation, clinical evidence verification, and full-process scientific research support (such as 3D film reading, first draft generation), and launched the “Knowledge Medical School” module to help physicians develop academically. Through strategic cooperation with Yunque Medical, we will further expand our reach to grassroots and rural doctors. In implementing the specialist model, the company has carried out pilot projects in specialist fields with top teams such as Peking University Cancer Hospital, Shandong First Medical University Cancer Hospital, and Guangzhou Medical University First Affiliated Hospital, covering the fields of gastrointestinal tumors, lung cancer and respiratory diseases.

JD opens a new physical examination store to speed up the improvement of the closed loop of “medical examination and drug diagnosis” offline

In terms of integrating all online and offline scenarios, JD Health continues to expand the service radius of the “medical examination and drug diagnosis” offline business format. Currently, users can reserve more than 400 inspection and testing projects online, of which 160 are on-site testing services; CT and nuclear magnetic imaging tests have been carried out in 15 cities across the country. The Beijing Yaao Branch and Tongzhou Branch of Jingdong Health General Clinic have successively opened, simultaneously providing medical examinations, dental, medical and aesthetic services, and introduced closed-loop management such as free 180-day review of more than 200 positive indicators and one-on-one follow-up examinations with private doctors, making high-quality offline medical services more accessible. At the same time, relying on continuous improvement of medical and health service capabilities, the company recently officially launched the “Medical Treatment in China” business to connect global patients with China's high-quality medical resources.

In the third quarter, JD nurses arrived home to officially launch the “filial piety care” service. Nursing nurses regularly visit the home every week to measure blood pressure, blood sugar, and blood oxygen for the elderly, establish family health records, continuously record changes in physical indicators, diet, exercise, daily status, etc., promptly alert potential health risks, and give professional care recommendations. Focusing on scenarios such as home health management for the elderly, chronic disease care, rehabilitation care, and family care support, JD Health uses nurses to provide home services and continuously explore health service models more suitable for Chinese families, making professional medical and health services more convenient for families.

In the third quarter of 2026, JD Health was driven by the “AI+ supply chain”. It not only maintained a strong momentum in online drug launches and AI medical services, but also continued to consolidate the all-scenario health service base through the deepening of the “medical examination and drug” business and the expansion of the “global circle of friends” at the Expo. In the future, JD Health will continue to explore innovative service models to provide users with more professional, convenient and accessible comprehensive health solutions.